FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used for treating atrial fibrillation in a patient. That is ensured by administering a solution of potassium aspartate & magnesium aspartate 250 ml intravenously drop-by-drop at rate of 15–45 drops per minute. Refralon is introduced in four steps: 5 mcg/kg – 5 mcg/kg – 10 mcg/kg – 10 mcg/kg.
EFFECT: invention provides restoration of normal sinus rhythm in the patient by reducing the risk of ventricular arrhythmias and cardiac arrest.
1 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING ATRIAL FIBRILLATION IN CASE OF MYOCARDIAL INFARCTION | 2005 |
|
RU2268713C1 |
| METHOD FOR TREATMENT OF CARDIAC RHYTHM DISORDER | 1991 |
|
RU2008903C1 |
| ANTI-ARRHYTHMIC PREPARATION | 2002 |
|
RU2223759C1 |
| METHOD FOR DESCRIBING ANATOMY OF HEART AND GREAT VESSELS | 2013 |
|
RU2539993C2 |
| METHOD FOR PREVENTION OF CARDIAC RHYTHM DISTURBANCE IN CORONARY BYPASS | 2009 |
|
RU2392939C1 |
| METHOD FOR PREVENTION OF RECURRENT ATRIAL FIBRILLATION FOLLOWING CARDIOSURGICAL OPERATIONS | 2014 |
|
RU2567920C1 |
| PHARMACEUTICAL COMPOSITION PREVENTING DEVELOPMENT OF PREEXCITATION SYNDROME | 2011 |
|
RU2453313C1 |
| METHOD FOR INDIVIDUAL SELECTION OF SUPPORTING DOSE OF LEVOSIMENDAN FOR TREATING ACUTE HEART FAILURE IN ELDERLY PATIENTS IN ACUTE PHASE OF MYOCARDIAL INFARCTION | 2015 |
|
RU2601666C1 |
| AGENT POSSESSING ANTIARRHYTHMIC, ANTIFIBRILLATORY, ANTI-ISCHEMIC ACTION, AND BASED PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2477130C1 |
| N-1-[(4-FLUOROPHENYL)-2-(1-ETHYL-4-PIPERIDYL)-ETHYL]-4-NITROBENZAMIDE HYDROCHLORIDE EXHIBITING ANTIARHYTHMIC AND ANTIFIBRILLATORY ACTIVITY | 2009 |
|
RU2415128C2 |
